PRISM MarketView Highlights Seven Small-Cap Lung Cancer Developers for Lung Cancer Awareness Month
PRISM MarketView has released a feature on seven small-cap companies developing therapies and diagnostics for lung cancer, coinciding with Lung Cancer Awareness Month. This comes after the FDA's decision not to approve a PD-1xVEGF bispecific antibody for EGFR-mutated lung cancer, emphasizing the importance of statistically significant survival benefits in clinical trials. The featured companies include Candel Therapeutics, MAIA Biotechnology, Cullinan Therapeutics, Crescent Biopharma, Tango Therapeutics, Personalis, and bioAffinity Technologies, all working on various solutions for lung cancer.
New Drug Application Submission Completed for Zipalertinib
Cullinan Therapeutics, Inc. announced that its partner Taiho Oncology, Inc. completed a New Drug Application (NDA) submission to the U.S. FDA for zipalertinib plus platinum-based chemotherapy. This submission is for the treatment of previously untreated, locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, based on positive Phase 3 REZILIENT3 trial data. The submission was made under the FDA's Real-Time Oncology Review program, and Cullinan is eligible for significant milestone payments upon regulatory approvals.
Cullinan's Nadim Ahmed: T-Cell Engagers Will Reach Autoimmune Patients Before Cell Therapy
Cullinan Therapeutics CEO Nadim Ahmed asserts that T-cell engagers will reach autoimmune patients before CAR-T cell therapy, primarily due to the latter's complexity and risk profile. The company is advancing CD19 and BCMA engagers as separate molecules to allow for both combination and sequencing approaches in various autoimmune diseases. Additionally, Cullinan's oncology asset, zipalertinib, is approaching two FDA approval decisions for EGFR exon 20 lung cancer, promising significant milestones and profit sharing with Taiho.
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2026 Financial Results
Cullinan Therapeutics (Nasdaq: CGEM) has provided a corporate update and announced its financial results for the third quarter ended September 30, 2026, showcasing significant progress across its immunology and oncology pipelines. Key milestones include advancement of velinotamig into a global study for autoimmune cytopenias, initiation of a potentially registrational Phase 2 study for CLN-049 in AML, and an NDA submission for zipalertinib in EGFR ex20ins NSCLC. The company reported $313.8 million in cash and investments, projecting a runway into 2029.
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) announced that its management team will participate in two upcoming investor conferences. CEO Nadim Ahmed and CMO Jeffrey Jones will speak at the Stifel 2026 Healthcare Conference on November 10, 2026, and the UBS Global Biopharma Conference 2026 on November 17, 2026. Webcasts of these fireside chats will be available on the company's investor relations website.
Cullinan Therapeutics Announces Presentations for CLN-049,
Cullinan Therapeutics will present four posters at the 68th ASH Annual Meeting, highlighting data for its T-cell engager programs, CLN-049 and velinotamig. CLN-049, a FLT3xCD3 T cell engager, shows updated anti-leukemic activity in Phase 1 for AML/MDS and has a "Trial in Progress" for newly diagnosed AML in combination with azacitidine and venetoclax. Velinotamig (CLN-803), a BCMAxCD3 T cell engager, will have presentations on its mechanism in autoimmune cytopenias and a "Trial in Progress" for immune thrombocytopenia and warm autoimmune hemolytic anemia.
Cullinan Oncology LLC (CGEM) Stock Price, Chart & Analysis
This article provides a detailed analysis of Cullinan Oncology LLC (CGEM) stock, covering its current price, market capitalization, key financial figures, and analyst forecasts. It highlights that the company does not pay dividends and that its revenue growth is currently flat, though analysts anticipate significant future growth. The report also addresses common investor questions about the stock's valuation, balance sheet strength, and 52-week price range.
Cullinan Therapeutics gains FDA clearance for velinotamig blood-disorder trial
Cullinan Therapeutics has received FDA and Australian regulatory clearance for a Phase 1b/2a trial of velinotamig, a T-cell engager, in adults with relapsing and refractory autoimmune immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA). The planned 72-participant study will assess the safety and tolerability of four subcutaneous doses over 48 weeks, with initiation estimated for late 2026 or early 2027. This clearance marks a significant step for Cullinan in developing targeted therapies for autoimmune diseases.
How Cullinan Oncology Inc. (CGEM) Affects Rotational Strategy Timing
This article analyzes Cullinan Oncology Inc. (CGEM) using AI models to suggest various trading strategies. It highlights divergent sentiment across different time horizons, indicating choppy market conditions and elevated downside risk for the stock. The report provides specific entry, target, and stop loss levels for Position Trading, Momentum Breakout, and Risk Hedging strategies.
Cullinan Therapeutics, Taiho Oncology Report 30.2% Intracranial Response Rate in Phase 2 Cancer Trial
Cullinan Therapeutics and Taiho Oncology announced that their drug zipalertinib achieved a 30.2% intracranial response rate in a Phase 2 cancer trial. This result indicates clinically meaningful efficacy. The full MT Newswires article requires a premium subscription to read.
Responses in the brain to an experimental lung cancer drug lasted a median 9.7 months.
Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. announced positive results from Cohort C of the Phase 2 REZILIENT2 trial for zipalertinib monotherapy in NSCLC patients with EGFR exon 20 insertion or uncommon EGFR mutations and active CNS metastases. The trial demonstrated an intracranial objective response rate of 30.2% and a median intracranial duration of response of 9.7 months in evaluable patients. These findings support further evaluation of zipalertinib in this difficult-to-treat patient population, with data to be presented at the ESMO Congress 2026.
Price-Driven Insight from (CGEM) for Rule-Based Strategy
This article provides a price-driven insight for Cullinan Oncology Inc. (NASDAQ: CGEM), highlighting divergent sentiment across all time horizons, suggesting choppy market conditions and elevated downside risk. It outlines three institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to aid rule-based investment decisions. The analysis points to no clear price positioning signal and a lack of additional long-term support.
BTIG Keeps Their Buy Rating on Cullinan Management (CGEM)
BTIG analyst Julian Harrison maintained a Buy rating on Cullinan Management (CGEM) with a $40.00 price target. This aligns with a Strong Buy consensus among analysts, who predict a 145.70% upside for the stock. Despite reporting a GAAP net loss of $53.7 million in the last quarter, other firms like H.C. Wainwright also maintained a Buy rating, citing potential for growth.
H.C. Wainwright reiterates Cullinan Oncology stock rating on NDA filing
H.C. Wainwright reiterated a Buy rating and $35 price target for Cullinan Oncology (NASDAQ: CGEM) after the company announced a rolling NDA submission for zipalertinib in combination with chemotherapy for first-line EGFR Ex20Ins+ NSCLC. The submission is backed by positive Phase 3 trial results, showing significantly improved overall response rate, duration of response, and progression-free survival compared to chemotherapy alone. A first-line approval would lead to a $100 million milestone payment for Cullinan, while a potential PDUFA date in February 2027 for post-platinum EGFR Ex20Ins+ NSCLC patients could trigger a $30 million payment.
Up to $100M hinges on first-line approval as Cullinan (CGEM) starts a lung cancer drug submission.
Cullinan Therapeutics, Inc. (CGEM) has initiated an FDA New Drug Application (NDA) submission for zipalertinib in combination with chemotherapy for previously untreated non-small cell lung cancer with specific EGFR mutations, utilizing the Real-Time Oncology Review program. The company expects to complete this submission by year-end 2026. This move follows positive Phase 3 trial results and positions Cullinan to receive up to $100 million in milestone payments upon U.S. approval for this first-line treatment.
H.C. Wainwright reiterates Cullinan Oncology stock rating on NDA filing By Investing.com
H.C. Wainwright has reaffirmed its Buy rating and $35 price target for Cullinan Oncology Inc. (NASDAQ:CGEM) following the company's announcement of a rolling NDA submission for zipalertinib. The drug, in combination with platinum-based chemotherapy, showed promising results in the Phase 3 REZILIENT3 trial for first-line EGFR Ex20Ins+ NSCLC, demonstrating improved overall response rate, duration of response, and progression-free survival. This news comes amidst other recent positive analyst updates and trial data, despite a recent stock decline.
Cullinan Therapeutics Initiates FDA NDA Submission for Zipalertinib Combo in First-Line EGFR Exon 20 Insertion NSCLC Following Phase 3 REZILIENT3 Results
Cullinan Therapeutics has begun the New Drug Application (NDA) submission process for zipalertinib combined with platinum-based chemotherapy for first-line EGFR exon 20 insertion NSCLC. This follows positive Phase 3 REZILIENT3 study results, showing significant progression-free survival improvements. The submission is under the FDA's Real-Time Oncology Review program, with completion anticipated by year-end 2026, and could lead to substantial milestone payments for Cullinan upon regulatory approval.
New Drug Application Submission Initiated for Zipalertinib Plus Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation NSCLC for Review Under FDA Real-Time Oncology Review Program
Cullinan Therapeutics has initiated a New Drug Application (NDA) submission to the FDA for zipalertinib in combination with chemotherapy for first-line treatment of EGFR exon 20 insertion mutation non-small cell lung cancer (NSCLC) under the Real-Time Oncology Review (RTOR) program. This submission is based on positive Phase 3 REZILIENT3 trial data showing improved progression-free survival. The company expects to complete the NDA submission by year-end 2026 and could receive significant milestone payments upon regulatory approvals.
Cullinan Therapeutics, Inc. (CGEM) stock price, news, quote and history
Cullinan Therapeutics, Inc. (CGEM) is a clinical-stage biopharmaceutical company focused on developing therapies for autoimmune diseases and cancer. The article provides current stock information, including a price of 14.95, and details its pipeline of clinical trials for various compounds like CLN-978, Velinotamig, and Zipalertinib. Financial highlights and analyst ratings are also included, with an average target price of 33.45.
Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
Cullinan Therapeutics will host a virtual event for analysts and institutional investors on September 14, 2026, at 8:00 a.m. ET. The event will discuss the results from the planned interim analysis of the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC, which met its primary endpoint of progression-free survival. These data are being presented at the IASLC 2026 World Conference on Lung Cancer.
Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio
Cullinan Therapeutics (Nasdaq: CGEM) has announced key fourth quarter 2026 milestones for its immunology and oncology T cell engager pipeline. The company plans to release multi-dose regimen data for CLN-978 in SLE, RA, and Sjögren's disease in December, and for Velinotamig in SLE at ACR Convergence 2026 in November. Additionally, updated data from the Phase 1 dose escalation study of CLN-049 in relapsed/refractory AML will be presented in December.
Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) announced that its CEO, Nadim Ahmed, and Chief Medical Officer, Jeffrey Jones, M.D., M.B.A., will participate in a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum. The event is scheduled for Thursday, September 24, 2026, at 1:30 p.m. ET. A webcast of their discussion will be accessible on the company's investor relations website.
Cullinan Therapeutics Highlights Fourth Quarter 2026 Milestones Across Immunology and Oncology T Cell Engager Portfolio
Cullinan Therapeutics is set to unveil significant updates for its immunology and oncology T-cell engager programs in Q4 2026. Key announcements include multi-dose regimen data for CLN-978 in various autoimmune diseases, velinotamig data for plasma cell-driven autoimmune diseases, and updated Phase 1 data for CLN-049 in relapsed/refractory AML. These updates highlight the company's progress in developing first- or best-in-class therapies for both autoimmune conditions and cancer.
Cullinan Therapeutics to present at Stifel immunology forum
Cullinan Therapeutics (NASDAQ: CGEM) announced that CEO Nadim Ahmed and CMO Jeffrey Jones will participate in the Stifel 2026 Virtual Immunology and Inflammation Forum. They are scheduled to hold a fireside chat on September 24, 2026, at 1:30 p.m. ET, which will be webcast on the company's investor relations website. The company is a clinical-stage biopharmaceutical firm focused on developing T cell engagers for autoimmune diseases and cancer.
Cullinan Therapeutics to Participate in the Stifel 2026 Virtual Immunology and Inflammation Forum
Cullinan Therapeutics (Nasdaq: CGEM) announced that its CEO, Nadim Ahmed, and Chief Medical Officer, Jeffrey Jones, M.D., M.B.A., will participate in a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum. The event is scheduled for Thursday, September 24, 2026, at 1:30 p.m. ET. A webcast will be available on the company's investor relations website.
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
The Phase 3 REZILIENT3 trial showed that zipalertinib combined with chemotherapy significantly improved progression-free survival by 6 months in first-line EGFR exon 20 insertion mutation non-small cell lung cancer patients. The combination therapy achieved a median PFS of 14.5 months compared to 8.5 months for chemotherapy alone, with a higher objective response rate. These positive results support zipalertinib plus chemotherapy as a potential new first-line treatment option for this specific lung cancer patient population.
BTIG raises Cullinan Oncology stock price target on trial data
BTIG raised its price target for Cullinan Oncology Inc. (CGEM) to $40 from $39, maintaining a Buy rating after positive Phase 3 trial results for zipalertinib. The drug, combined with chemotherapy, significantly reduced disease progression in certain lung cancer patients, leading to potential milestone payments from Taiho Pharmaceuticals. Other firms like UBS, Stifel, and TD Cowen also reaffirmed positive ratings on CGEM following these developments.
BTIG raises Cullinan Oncology stock price target on trial data
BTIG has increased its price target for Cullinan Oncology (NASDAQ:CGEM) to $40 from $39, maintaining a Buy rating, following positive Phase 3 trial results for its drug zipalertinib. The drug, in combination with chemotherapy, reduced disease progression risk by 50% in certain lung cancer patients and achieved a median progression-free survival of 14.5 months. This positive development could lead to significant milestone payments for Cullinan Oncology.
Cullinan Oncology stock rating reaffirmed at Buy by TD Cowen
TD Cowen has reaffirmed its Buy rating on Cullinan Oncology Inc. (NASDAQ:CGEM), projecting peak sales of $225 million for its drug, with potential upside to $1 billion due to promising REZILIENT3 trial results. The company recently announced positive Phase 3 trial results for zipalertinib and received favorable feedback from the FDA for CLN-049, indicating significant progress in its therapeutic pipeline. Despite being considered overvalued by some metrics, analysts maintain price targets between $23 and $42, reflecting confidence in its future.
Stifel reiterates Cullinan Oncology stock Buy rating on trial data
Stifel reiterated a Buy rating and $28.00 price target for Cullinan Oncology Inc. (NASDAQ:CGEM) after positive Phase 3 trial data for its cancer drug candidate, Zipalertinib, which showed a significant progression-free survival benefit. The stock has seen substantial gains, with InvestingPro analysis noting that while current trading suggests overvaluation, ongoing developments, including potential milestones and upcoming multidose data, support the firm's investment thesis. Other analysts like UBS and TD Cowen have also raised price targets following the trial results, highlighting the company's progress in its drug pipeline.
Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
Cullinan Therapeutics (Nasdaq: CGEM) is hosting a virtual event for analysts and investors to discuss the results from the Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy. These results were presented at the IASLC 2026 World Conference on Lung Cancer. The event will include CEO Nadim Ahmed and Chief Medical Officer Jeffrey Jones, MD, MBA.
Taiho Pharmaceutical Co., Ltd., Taiho Oncology, Inc., and Cullinan Therapeutics, Inc. Reports Results From Phase 3 REZILIENT3 Trial Evaluating Zipalertinib Plus Chemotherapy In First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics announced positive results from their Phase 3 REZILIENT3 trial. The trial evaluated zipalertinib plus chemotherapy for the first-line treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer, showing a statistically significant and clinically meaningful improvement in progression-free survival. This achievement is considered a significant milestone for zipalertinib as a future growth driver, although it does not impact the current fiscal year's earnings forecast.
Cullinan Therapeutics to Host Virtual Analyst and Investor Event Today to Feature Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
Cullinan Therapeutics will host a virtual event for analysts and institutional investors to discuss the results from the interim analysis of its Phase 3 REZILIENT3 trial. The trial investigates zipalertinib plus chemotherapy, with data presented at the IASLC 2026 World Conference on Lung Cancer. The event will include remarks from CEO Nadim Ahmed and CMO Jeffrey Jones, MD, MBA.
Cullinan Therapeutics Shares Fall 6.3% After Phase 3 Zipalertinib Trial Results
Cullinan Therapeutics shares dropped 6.3% after announcing Phase 3 trial results for zipalertinib in non-small cell lung cancer. The REZILIENT3 trial met its primary endpoint, showing zipalertinib plus chemotherapy extended median progression-free survival by 6.0 months compared to chemotherapy alone. The companies plan to discuss these positive results with health authorities for potential availability to patients.
Zipalertinib Plus Chemotherapy Demonstrates 6-Month Median Progression-Free Survival Benefit in REZILIENT3 Phase 3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
The Phase 3 REZILIENT3 trial showed that zipalertinib combined with chemotherapy significantly improved progression-free survival by 6.0 months in patients with first-line EGFR exon 20 insertion mutation non-small cell lung cancer (NSCLC). This combination also resulted in higher objective response rates compared to chemotherapy alone. These findings suggest zipalertinib plus chemotherapy could be a new first-line treatment option for this specific patient population.
Cullinan Therapeutics to Host Virtual Analyst and Investor Event to Showcase Zipalertinib Plus Chemotherapy Phase 3 REZILIENT3 Data Presented at the IASLC 2026 World Conference on Lung Cancer
Cullinan Therapeutics will host a virtual event on September 14, 2026, to discuss the interim analysis results of its Phase 3 REZILIENT3 trial for zipalertinib plus chemotherapy. The trial, focusing on first-line EGFR exon 20 insertion mutation-positive NSCLC, met its primary endpoint of progression-free survival. These findings will be presented at the IASLC 2026 World Conference on Lung Cancer.
Understanding the Setup: (CGEM) and Scalable Risk
Cullinan Oncology Inc. (NASDAQ: CGEM) is showing weak near-term sentiment despite long-term strength, according to AI models. The analysis highlights a mid-channel oscillation pattern and presents three distinct trading strategies: a long position trading strategy, a breakout strategy, and a short risk hedging strategy, each with specific entry, target, and stop-loss levels. The article emphasizes significant risk-reward potential for a short setup, targeting 11.6% downside versus 0.3% risk.
Cullinan Oncology stock hits 52-week high at 23.07 USD By Investing.com
Cullinan Oncology stock recently hit a 52-week high of $23.07, demonstrating a 200% increase over the past year and a 122% year-to-date return, with a market capitalization of $1.48 billion. Despite this strong performance, InvestingPro suggests the stock may be overvalued relative to its Fair Value. The company has also announced positive clinical trial results for its oncology and autoimmune drug candidates, leading to increased price targets from analysts like UBS and continued progress in its drug development pipeline.
Taiho, Cullinan trial results selected for lung cancer conference
Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. announced that results from their Phase 3 REZILIENT3 trial will be presented at the 2026 World Conference on Lung Cancer. The trial, which studied zipalertinib for the first-line treatment of EGFR exon 20 insertion mutation-positive non-small cell lung cancer, met its primary endpoint of progression-free survival. Zipalertinib is an investigational drug being developed jointly by Taiho Oncology and Cullinan Therapeutics.
Tokyo’s Taiho and Cullinan Announce Positive Phase 3 Lung Cancer Results
Taiho Pharmaceutical, Taiho Oncology, and Cullinan Therapeutics announced positive Phase 3 results for zipalertinib plus chemotherapy in non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations. The REZILIENT3 trial met its primary endpoint of improved progression-free survival, positioning zipalertinib as a potential first-line oral therapy for this underserved patient population. The companies plan to seek U.S. regulatory approval and present full results at an upcoming medical conference.
Taiho, Cullinan trial results selected for lung cancer conference
Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. announced that results from their Phase 3 REZILIENT3 trial will be presented at the 2026 World Conference on Lung Cancer. The trial, which evaluated zipalertinib plus chemotherapy for non-small cell lung cancer with EGFR exon 20 insertion mutations, met its primary endpoint of progression-free survival. The presentation will detail these findings at a Presidential Symposium in September 2026.
Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competition
Taiho Pharmaceutical and Cullinan Therapeutics announced that their candidate zipalertinib met its primary endpoint in the REZILIENT3 global Phase 3 study for advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, showing a significant improvement in progression-free survival (PFS) when combined with chemotherapy. This success paves the way for a potential FDA filing as a first-line treatment, adding to its current FDA review as a monotherapy for previously treated NSCLC. If approved, zipalertinib would compete with existing first-line therapies like Dizal Pharmaceutical and AstraZeneca’s Zegfrovy and Johnson & Johnson’s Rybrevant.
Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer
Taiho Oncology, Inc. and Cullinan Therapeutics, Inc. announced that data from their Phase 3 REZILIENT3 trial of zipalertinib plus chemotherapy for first-line EGFR exon 20 insertion mutation non-small cell lung cancer (NSCLC) has been selected for presentation at the IASLC 2026 World Conference on Lung Cancer. The presentation will occur during the Presidential Symposium 2 and will detail the planned interim analysis results, which met the primary endpoint of progression-free survival. Zipalertinib is an investigational orally available small molecule designed to target activating mutations in EGFR, specifically exon 20 insertion mutations.
Cullinan's lung cancer trial met its main goal; results are set for presentation in September
Cullinan Therapeutics (CGEM) announced that its Phase 3 REZILIENT3 trial for zipalertinib plus chemotherapy in first-line EGFR exon 20 insertion mutation NSCLC met its primary endpoint of progression-free survival. The positive results have been selected for presentation at the Presidential Symposium 2 of the IASLC 2026 World Conference on Lung Cancer in September 2026. This trial evaluated zipalertinib in combination with chemotherapy against chemotherapy alone for patients with this specific type of non-small cell lung cancer.
UBS raises Cullinan Oncology stock price target to $27 on trial data
UBS has increased its price target for Cullinan Oncology Inc. (NASDAQ:CGEM) to $27 from $24, while maintaining a Buy rating. This adjustment follows positive Phase 3 trial results for zipalertinib in treating first-line EGFR exon 20 insertion non-small cell lung cancer. The firm also raised the probability of success for zipalertinib in this indication to 85% from 40%, projecting significant peak sales potential.
UBS raises Cullinan Oncology stock price target to $27 on trial data
UBS has increased its price target for Cullinan Oncology (NASDAQ:CGEM) to $27 from $24, maintaining a Buy rating, following positive Phase 3 trial results for zipalertinib. The drug, developed with Taiho, showed significant progression-free survival benefit in first-line EGFR exon 20 insertion non-small cell lung cancer, leading UBS to raise its probability of success for zipalertinib in this indication to 85%. Despite the stock's recent surge and proximity to its 52-week high, InvestingPro suggests it may be overvalued.
Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced that their Phase 3 REZILIENT3 trial met its primary endpoint of progression-free survival. The study evaluated zipalertinib plus platinum-based chemotherapy for first-line treatment of NSCLC with EGFR exon 20 insertion mutations, showing statistically significant and clinically meaningful improvement. The companies plan to pursue U.S. regulatory approval for this combination regimen based on these positive interim results.
Cullinan Therapeutics, Inc. - Common Stock (CGEM) Stock Price, News, Quote & History
This article provides comprehensive information on Cullinan Therapeutics, Inc. (CGEM), including its current stock price, financial metrics, and a history of recent news and press releases. The company, a biopharmaceutical firm, focuses on developing cancer therapies and has announced several key clinical milestones and FDA designations for its drug candidates.
Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap Up After Analyst Upgrade
Cullinan Therapeutics (NASDAQ:CGEM) shares gapped up after Wedbush raised its price target from $39 to $42 and maintained an "outperform" rating. The company, which remains loss-making, currently has a "Moderate Buy" consensus from analysts with an average price target of $32.86. Insider selling by Jennifer Michaelson was reported, though institutional investors have recently increased their holdings.
Zipalertinib Plus Chemotherapy Meets Primary Endpoint of Progression-Free Survival in Planned Interim Analysis of Phase 3 REZILIENT3 Trial in First-Line EGFR Exon 20 Insertion Mutation Non-Small Cell Lung Cancer
Taiho Oncology, Taiho Pharmaceutical, and Cullinan Therapeutics announced that their Phase 3 REZILIENT3 trial for zipalertinib plus chemotherapy met its primary endpoint of progression-free survival in patients with first-line EGFR exon 20 insertion mutation non-small cell lung cancer. The study showed a statistically significant and clinically meaningful improvement in PFS with manageable safety. The companies plan to seek U.S. regulatory approval for this combination regimen based on these positive interim results.